10x Genomics, Inc. — Revenue by Fiscal Year
9 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/56d4af1b-b20d-4047-8a58-cd642957db54/serie/revenue
| Fiscal year | Revenue | Period | Evidence |
|---|---|---|---|
| FY 2025 | $642.8M | 2025-01-01 – 2025-12-31 | evidence 0001628280-26-007822 |
| FY 2024 | $610.8M | 2024-01-01 – 2024-12-31 | evidence 0001770787-25-000013 |
| FY 2023 | $618.7M | 2023-01-01 – 2023-12-31 | evidence 0001770787-24-000017 |
| FY 2022 | $516.4M | 2022-01-01 – 2022-12-31 | evidence 0001770787-23-000012 |
| FY 2021 | $490.5M | 2021-01-01 – 2021-12-31 | evidence 0001770787-22-000015 |
| FY 2020 | $298.8M | 2020-01-01 – 2020-12-31 | evidence 0001770787-21-000009 |
| FY 2019 | $245.9M | 2019-01-01 – 2019-12-31 | evidence 0001770787-21-000009 |
| FY 2018 | $146.3M | 2018-01-01 – 2018-12-31 | evidence 0001770787-21-000009 |
| FY 2017 | $71.1M | 2017-01-01 – 2017-12-31 | evidence 0001193125-20-052640 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
10x Genomics, Inc. — all facts · Net Income · Operating Income